Predictive model for chemotherapy-associated venous thrombosis
| Patient characteristic . | Risk score . |
|---|---|
| Site of cancer | |
| Very high risk (stomach, pancreas) | 2 |
| High risk (lung, lymphoma, gynecologic, bladder, testicular) | 1 |
| Prechemotherapy platelet count ≥350 × 109/L | 1 |
| Hemoglobin level < 100 g/L or use of red cell growth factors | 1 |
| Prechemotherapy leukocyte count >11 × 109/L | 1 |
| Body mass index ≥ 35 kg/m2 | 1 |
| Patient characteristic . | Risk score . |
|---|---|
| Site of cancer | |
| Very high risk (stomach, pancreas) | 2 |
| High risk (lung, lymphoma, gynecologic, bladder, testicular) | 1 |
| Prechemotherapy platelet count ≥350 × 109/L | 1 |
| Hemoglobin level < 100 g/L or use of red cell growth factors | 1 |
| Prechemotherapy leukocyte count >11 × 109/L | 1 |
| Body mass index ≥ 35 kg/m2 | 1 |
From Khorana et al.59